<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04846816</url>
  </required_header>
  <id_info>
    <org_study_id>GN18CA193</org_study_id>
    <nct_id>NCT04846816</nct_id>
  </id_info>
  <brief_title>A Study to Assess Safety and Efficacy of a Novel Patch Infusor Device and Novel SUBCUTaneous Furosemide Formulation Combination in Patients With Heart Failure</brief_title>
  <acronym>SUB CUT P1</acronym>
  <official_title>An Open Label, Single Dose Study to Assess Safety and Efficacy of a Novel Patch Infusor Device and Novel SUBCUTaneous Furosemide Formulation Combination in Patients With Heart Failure: a Phase I Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SQ Innovation, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Greater Glasgow and Clyde</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SQ Innovation, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-centre, prospective, open-label, non-comparative clinical trial assessing&#xD;
      the on-body performance of an investigational drug delivery device (SQIN-Infusor) in patients&#xD;
      hospitalised due to HF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigational product consists of a novel higher concentration (30mg/mL) furosemide&#xD;
      formulation developed for subcutaneous administration and a novel patch pump placed on the&#xD;
      abdominal skin. This trial will investigate the on body performance of novel patch pump&#xD;
      delivering the novel formulation. Study parameters include pharmacokinetic measurements and&#xD;
      diuretic response following subcutaneous administration of 80mg of furosemide solution in&#xD;
      2.7mL in patients with heart failure (HF). Recruitment will be restricted to 1 site with a&#xD;
      recruitment target of 20 patients. All trial related activities will be conducted in an&#xD;
      inpatient environment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Actual">August 13, 2021</completion_date>
  <primary_completion_date type="Actual">August 13, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The drug and device combination is called SQIN-01. SQIN-01 is a combination of SQIN-Infusor and SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the safety, tolerability, efficacy and on-body performance of a novel patch infusor device and novel furosemide formulation combination (SQIN-01).</measure>
    <time_frame>24 hours from start of infusion</time_frame>
    <description>Safety as determined by treatment emergent adverse events and adverse drug events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion site pain</measure>
    <time_frame>During 5 hour infusion</time_frame>
    <description>Measured on a scale of 0 = no pain to 10 = most pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Any device failures</measure>
    <time_frame>During 5 hour infusion</time_frame>
    <description>Any device failures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum furosemide concentration</measure>
    <time_frame>At baseline</time_frame>
    <description>Serum furosemide concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum furosemide concentration</measure>
    <time_frame>At 60 minutes</time_frame>
    <description>Serum furosemide concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum furosemide concentration</measure>
    <time_frame>At 240 minutes</time_frame>
    <description>Serum furosemide concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine volume</measure>
    <time_frame>8 hours</time_frame>
    <description>Urine volume (ml) in urine collected 8 hours after start of SQIN-Furosemide infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium concentration in urine</measure>
    <time_frame>8 hours</time_frame>
    <description>Sodium concentration (mmol) in urine collected 8 hours after start of SQIN-Furosemide infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of local skin reactions</measure>
    <time_frame>After 5 hour infusion</time_frame>
    <description>Presence of local skin reactions on examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient acceptability</measure>
    <time_frame>After 5 hour infusion</time_frame>
    <description>Patient acceptability using System Usability Scale - from 0 to 100 with a lower number correlating to poor usability and a higher number correlating to better usability by patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>SQIN-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The drug and device combination is called SQIN-01. SQIN-01 is a combination of SQIN-Infusor and SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>SQIN-01</intervention_name>
    <description>The drug and device combination is called SQIN-01. SQIN-01 is a combination of SQIN-Infusor and SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.</description>
    <arm_group_label>SQIN-01</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Written informed consent&#xD;
&#xD;
               -  Male or female ≥18 years of age&#xD;
&#xD;
               -  Meet ESC criteria for diagnosis of HF(4)&#xD;
&#xD;
               -  Inpatient with a primary diagnosis of HF requiring treatment with intravenous&#xD;
                  furosemide at dose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Unable to consent to inclusion in study due to lack of capacity&#xD;
&#xD;
               -  Requiring treatment with intravenous furosemide at dose &gt;200 mg per day as&#xD;
                  determined by the usual care team&#xD;
&#xD;
               -  Current inotropes, vasopressors or intra-aortic balloon pump therapy&#xD;
&#xD;
               -  Concomitant use of diuretics in 12 hours preceding administration of study drug&#xD;
                  with SQIN-Infusor&#xD;
&#xD;
               -  Systolic blood pressure (SBP) &lt;90 mmHg&#xD;
&#xD;
               -  Pregnancy or breastfeeding&#xD;
&#xD;
               -  Left sided valve disease with planned surgery or percutaneous intervention&#xD;
&#xD;
               -  Type 1 myocardial infarction during index hospitalisation (type 2 myocardial&#xD;
                  infarctions are allowed)(5)&#xD;
&#xD;
               -  Any surgical or medical condition which prevents patient from ambulation during&#xD;
                  the infusion&#xD;
&#xD;
               -  Renal impairment, defined as eGFR &lt; 30 mL/min/1.73 m2 at screening.&#xD;
&#xD;
               -  Patient on active cardiac transplant waiting list&#xD;
&#xD;
               -  Potassium &lt;3.0 mmol/L&#xD;
&#xD;
               -  Potassium &gt;6.0 mmol/L&#xD;
&#xD;
               -  Sodium &lt;125 mmol/L&#xD;
&#xD;
               -  Any contraindications for furosemide administration as per furosemide SmPC&#xD;
&#xD;
               -  Any surgical or medical conditions, which in the opinion of the investigator may&#xD;
                  pose an undue risk to the subject, interfere with participation in the study or&#xD;
                  which may affect the integrity of the data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Petrie, MBChB</last_name>
    <role>Study Chair</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital, NHS Greater Glasgow &amp; Clyde</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>to publish</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

